Financing ·
On August 28, 2026, Kazia Therapeutics Limited priced an underwritten public offering of 2,580,000 American Depositary…
KZIAKazia Therapeutics Ltd
On August 28, 2026, Kazia Therapeutics Limited priced an underwritten public offering of 2,580,000 American Depositary Shares (ADSs), each representing 500 ordinary shares. The offering includes pre-funded warrants to purchase up to 303,200 ADSs and accompanying Series A and Series B Warrants to purchase up to 2,243,478 and 2,064,000 ADSs, respectively. The combined public offering price is $15.50 per ADS and accompanying warrants, generating expected gross proceeds of approximately $40 million for the company. Additional potential gross proceeds of up to $80 million may be realized upon exercise of the Series A and B Warrants at prices of $17.825 and $19.375 per ADS. The net proceeds are intended to fund clinical development of paxalisib, including Phase 1b trials in advanced triple-negative breast cancer and expansions into HR+/HER2- breast cancer, as well as for working capital. The offering closed on or about August 31, 2026. Kazia Therapeutics is an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology.